{"id":20362,"date":"2026-10-20T18:25:05","date_gmt":"2026-10-20T12:55:05","guid":{"rendered":"https:\/\/sunpharma.com\/?p=20362"},"modified":"2026-10-20T18:56:13","modified_gmt":"2026-10-20T13:26:13","slug":"sun-pharma-nccn-guidelines-update","status":"publish","type":"post","link":"https:\/\/sunpharma.com\/he\/blog\/sun-pharma-nccn-guidelines-update\/","title":{"rendered":"Sun Pharma Announces UNLOXCYT\u00ae (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma"},"content":{"rendered":"

Read More<\/a><\/p>","protected":false},"excerpt":{"rendered":"

Read More<\/p>","protected":false},"author":4,"featured_media":17391,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-20362","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pressreleases"],"yoast_head":"\nSun Pharma Announces UNLOXCYT\u00ae (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma - Sun Pharmaceutical Industries Ltd.<\/title>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"he_IL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sun Pharma Announces UNLOXCYT\u00ae (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma - Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"og:description\" content=\"Read More\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sunpharma.com\/he\/blog\/sun-pharma-nccn-guidelines-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Sun Pharmaceutical Industries Ltd.\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-20T12:55:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-20T13:26:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press-release-sign-scaled-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"626\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"ananthi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u05e0\u05db\u05ea\u05d1 \u05e2\u05dc \u05d9\u05d3\" \/>\n\t<meta name=\"twitter:data1\" content=\"ananthi\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sun Pharma Announces UNLOXCYT\u00ae (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma - Sun Pharmaceutical Industries Ltd.","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"he_IL","og_type":"article","og_title":"Sun Pharma Announces UNLOXCYT\u00ae (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma - Sun Pharmaceutical Industries Ltd.","og_description":"Read More","og_url":"https:\/\/sunpharma.com\/he\/blog\/sun-pharma-nccn-guidelines-update\/","og_site_name":"Sun Pharmaceutical Industries Ltd.","article_published_time":"2026-10-20T12:55:05+00:00","article_modified_time":"2026-10-20T13:26:13+00:00","og_image":[{"width":626,"height":416,"url":"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press-release-sign-scaled-1.jpg","type":"image\/jpeg"}],"author":"ananthi","twitter_card":"summary_large_image","twitter_misc":{"\u05e0\u05db\u05ea\u05d1 \u05e2\u05dc \u05d9\u05d3":"ananthi"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/#article","isPartOf":{"@id":"https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/"},"author":{"name":"ananthi","@id":"https:\/\/sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa"},"headline":"Sun Pharma Announces UNLOXCYT\u00ae (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma","datePublished":"2026-10-20T12:55:05+00:00","dateModified":"2026-10-20T13:26:13+00:00","mainEntityOfPage":{"@id":"https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/"},"wordCount":26,"commentCount":0,"image":{"@id":"https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/#primaryimage"},"thumbnailUrl":"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press-release-sign-scaled-1.jpg","articleSection":["Press Releases"],"inLanguage":"he-IL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/","url":"https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/","name":"Sun Pharma Announces UNLOXCYT\u00ae (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma - Sun Pharmaceutical Industries Ltd.","isPartOf":{"@id":"https:\/\/sunpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/#primaryimage"},"image":{"@id":"https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/#primaryimage"},"thumbnailUrl":"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press-release-sign-scaled-1.jpg","datePublished":"2026-10-20T12:55:05+00:00","dateModified":"2026-10-20T13:26:13+00:00","author":{"@id":"https:\/\/sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa"},"breadcrumb":{"@id":"https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/#breadcrumb"},"inLanguage":"he-IL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/"]}]},{"@type":"ImageObject","inLanguage":"he-IL","@id":"https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/#primaryimage","url":"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press-release-sign-scaled-1.jpg","contentUrl":"https:\/\/sunpharma.com\/wp-content\/uploads\/2025\/05\/press-release-sign-scaled-1.jpg","width":626,"height":416},{"@type":"BreadcrumbList","@id":"https:\/\/sunpharma.com\/blog\/sun-pharma-nccn-guidelines-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sunpharma.com\/"},{"@type":"ListItem","position":2,"name":"Sun Pharma Announces UNLOXCYT\u00ae (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/sunpharma.com\/#website","url":"https:\/\/sunpharma.com\/","name":"Sun Pharmaceutical Industries Ltd.","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sunpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"he-IL"},{"@type":"Person","@id":"https:\/\/sunpharma.com\/#\/schema\/person\/c7269b4a3d6a22d46bfb1554af8093fa","name":"ananthi","image":{"@type":"ImageObject","inLanguage":"he-IL","@id":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/09645f2c6ef6bbb3a78db22600040d547bed4438a393e0671d168d69d193bc19?s=96&d=mm&r=g","caption":"ananthi"},"url":"https:\/\/sunpharma.com\/he\/blog\/author\/ananthi\/"}]}},"_links":{"self":[{"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/20362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/comments?post=20362"}],"version-history":[{"count":4,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/20362\/revisions"}],"predecessor-version":[{"id":20368,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/posts\/20362\/revisions\/20368"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/media\/17391"}],"wp:attachment":[{"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/media?parent=20362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/categories?post=20362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sunpharma.com\/he\/wp-json\/wp\/v2\/tags?post=20362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}